Sunday 8 September 2024
Home      All news      Contact us      RSS     
zimbabweonlinenews - 4 days ago

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […] The post Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability appeared first on Zimbabwe Online News.


Latest News
Hashtags:   

Recursion

 | 

Announces

 | 

Phase

 | 

First

 | 

Disease

 | 

Investigational

 | 

Treatment

 | 

Symptomatic

 | 

Cerebral

 | 

Cavernous

 | 

Malformation

 | 

Primary

 | 

Endpoint

 | 

Safety

 | 

Tolerability

 | 

Sources